Dexamethasone affects human fetal adrenal steroidogenesis and subsequent ACTH response in an ex vivo culture model

Administration of dexamethasone (DEX) has been used experimentally to suppress androgenization of external genitalia in 46,XX fetuses with congenital adrenal hyperplasia. Despite this, the prenatal biological mechanism-of-action of DEX on fetal development is not known. This study aimed to examine d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in endocrinology (Lausanne) 2023-07, Vol.14, p.1114211-1114211
Hauptverfasser: Melau, Cecilie, Gayete Mor, Berta, Lundgaard Riis, Malene, Nielsen, John E, Dreisler, Eva, Aaboe, Kasper, Tutein Brenøe, Pia, Langhoff Thuesen, Lea, Juul Hare, Kristine, Mitchell, Rod T, Frederiksen, Hanne, Juul, Anders, Jørgensen, Anne
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Administration of dexamethasone (DEX) has been used experimentally to suppress androgenization of external genitalia in 46,XX fetuses with congenital adrenal hyperplasia. Despite this, the prenatal biological mechanism-of-action of DEX on fetal development is not known. This study aimed to examine direct effects of DEX on human fetal adrenal (HFA) steroidogenic activity including possible effects on the subsequent response to ACTH-stimulation. Human fetal adrenal (HFA) tissue from 30 fetuses (1 trimester) were cultured with A) DEX (10 µm) for 14 days, or B) DEX (10 µm) for 10 days followed by ACTH (1 nM) for 4 days. DEX-mediated effects on HFA morphology, viability, and apoptosis (immunohistochemistry), gene expression (quantitative PCR), and steroid hormone secretion (LC-MS/MS) were investigated. DEX-treatment caused decreased androstenedione (p
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2023.1114211